GlassScriptPhysician profile
Karen M Pace
NPI 1528311800
$1,479.96
in general payments reported to CMS, 2019-2025
9 companies · $13.95 in 2025
The $13.95 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $468 · 2023: $544 · 2024: $454 · 2025: $13.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $481.97 | 2022-2024 | Zepbound, Mounjaro |
| Novo Nordisk INC | $476.94 | 2022-2024 | Wegovy, Saxenda |
| Intra-Sana Laboratories | $182.93 | 2023-2024 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Amgen INC. | $120.59 | 2022 | |
| Janssen Scientific Affairs, LLC | $110.55 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.95 | 2022 | |
| Currax Pharmaceuticals LLC | $31.80 | 2023-2025 | Contrave |
| Pfizer INC. | $22.23 | 2023 | |
| Vivus LLC | $21.00 | 2024 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.